Psilocybin: How it Rewires the Brain, Its Therapeutic Benefits, Mechanisms, and Risks

This episode delves into psilocybin, a psychedelic that profoundly alters consciousness and perception, both during and long after its use. The core mechanism involves psilocybin mimicking serotonin, specifically activating the serotonin 2A (5-HT2A) receptor in a potent and selective manner. This selective activation, unlike the broad effects of SSRIs, triggers significant neuroplasticity in brain regions like the neocortex, including the prefrontal and visual cortices, which are crucial for memory, perception, context, and thought patterns. The active compound, psilocin, is responsible for these changes, and its conversion from psilocybin influences the duration and neuroplastic window of the experience.

The discussion highlights that while psilocybin induces neuroplasticity, its therapeutic efficacy is not guaranteed and depends heavily on specific conditions, often referred to as "set and setting." Key factors include whether the session is conducted with eyes closed (to encourage introspection over external visual hallucinations), the type of music played, dosage levels, and the integration of the experience through post-session therapy. Clinical trials are showing remarkable success, with psilocybin outperforming traditional antidepressants like SSRIs in providing long-lasting relief for major depression, as well as showing promise for addiction, OCD, and eating disorders.

A critical distinction is made between psilocybin's targeted 5-HT2A activation and the non-specific serotonin increase caused by SSRIs, which often leads to diverse side effects. The episode emphasizes that for neuroplasticity to be truly therapeutic, it must be adaptive, enabling individuals to function better in life. This underscores the importance of structured, guided sessions and the period following the psychedelic experience for integrating insights and changes into daily life.

Safety is a paramount concern, with strict contraindications outlined. Psilocybin use is strongly discouraged for individuals under 25, as their brains are still undergoing natural developmental neuroplasticity. Furthermore, it is contraindicated for anyone with a personal or close family history of psychotic disorders (e.g., schizophrenia, bipolar depression, borderline personality disorder) due to the risk of triggering psychotic episodes. The legal status of psilocybin as a Schedule I drug in most places, with limited decriminalized or therapeutically approved areas, is also stressed, reinforcing that its use should only be considered within proper clinical or research settings.

"Psilocybin is a psychedelic, meaning it modifies the psyche. And in doing so, it changes our level of consciousness."

"Psilocybin main effect is to mimic serotonin. But it does it in a very specific way because it activates a subset of serotonin receptors in a very strong fashion leading to neuroplasticity at the level of the neural circuits..."

"Psilocin is the actual compound that goes into the brain to create all the changes in consciousness and all the rewiring effects that we associate with psilocybin."

"Much of the positive changes that are possible with proper-- and I do want to underscore proper psilocybin therapeutic approaches, takes place after the session in which one feels all typical or typically associated effects of psilocybin..."

"Just because something invokes neuroplasticity changes in brain circuitry does not mean that it's therapeutic, or I should say, does not necessarily mean that it's therapeutic. For neuroplasticity to be therapeutic, it has to be adaptive, it has to allow someone to function better in life than they did previously."

"Psilocybin mainly binds to and activates the so-called serotonin to a receptor."

"The clinical trials for psilocybin are outperforming standard therapy and outperforming so-called SSRIs and various other antidepressants in terms of providing depression relief in ways that are frankly staggering not just to me, but to the psychiatric community at large."

"If one's goal is to derive long-lasting benefit from the psilocybin experience, it's very clear that having an eye mask or some other eye covering or something that ensures that one's eyes are closed for the majority, if not, the entire psilocybin session is going to be very useful because it's going to limit the extent to which one is focused on those outside changes in visual perception a.k.a. hallucinations and rather will allow the person to go inward..."